STXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Stereotaxis, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.01+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $101.03M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
52.7%−18.5 pts over 5 years
Operating margin
-68.3%−43.1 pts over 5 years
Net margin
-66.8%−41.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +20.3% | +4.8% | +4.0% | -1.5% | |
| Gross profit | +17.0% | -2.6% | -2.1% | -4.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 27.0% | -23.2% | -221.3% | |
| Return on assets | -26.5% | -13.4% | -43.7% | |
| Current ratio | 0.54 | 3.88 | 1.51 | |
| Interest coverage | -2.6× | – | – | |
| Inventory turnover | 1.5× | 3.0× | 1.7× | |
| Capex to revenue | 1.3% | 0.3% | 0.3% | |
| Diluted shares | 22M | 73M | 91M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Stereotaxis generated $42.68M from operations and spent $4.27M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$42.68M
Used
$4.27M
Capital expenditure$4.27M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-66.8%
×Asset turnover0.65×
×Equity multiplier5.06×
=Return on equity, FY2025-221.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -66.8% | 0.65× | 5.06× | -221.3% |
| FY2024 | -89.3% | 0.61× | 3.95× | -214.5% |
| FY2023 | -77.4% | 0.56× | 2.23× | -97.0% |
| FY2022 | -65.0% | 0.49× | 1.90× | -60.8% |
| FY2021 | -30.6% | 0.60× | 1.70× | -31.3% |
| FY2020 | -25.0% | 0.54× | 1.73× | -23.2% |
| FY2019 | -15.9% | 0.93× | 2.58× | -38.1% |
| FY2018 | 0.4% | 2.01× | -1.16× | -0.9% |
| FY2017 | -18.9% | 1.97× | -0.66× | 24.5% |
| FY2016 | -16.4% | 1.61× | -1.02× | 27.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$21.64M
- Cash generatingOperating cash flow above zero-$13.69M
- Return on assets improvedROA up on the prior year-57.4% → -46.3%
- Earnings backed by cashOperating cash flow above net income-$13.69M vs -$21.64M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.22 → 1.51
- No dilutionShare count did not rise85M → 91M
- Gross margin improvedGross margin up on the prior year54.22% → 52.73%
- More efficientAsset turnover rose0.64 → 0.69